Doug Long of IQVIA Discusses the Effect of the COVID-19 Pandemic on Healthcare, Pharmaceutical Market
Long, the vice president of industry relations at IQVIA, gives his take on the lingering effects of the pandemic on the healthcare sector and pharmaceutical market.
Weight-Loss Drugs: Why This Time It May Be a Different Story | 2022 PBMI Annual National Conference
The harm caused by weight-loss drugs have overwhelmed any benefit they may have. The repurposed diabetes drugs like Wegovy (semaglutide) have a strong safety profile, said presented at the annual Pharmacy Benefit Management Institute meeting.
WellDyne's David Skomo Highlights the Need to Reframe How Obesity Is Viewed
Payers need to reframe how they view obesity as not just a health and wellness issue, but as a progressive chronic disease that needs medication, explained David Skomo, RPh, chief operations officer at WellDyne.
A Real-Time Benefit Check Success Story | 2022 PBMI Annual National Conference
Executives at Arrive Health and OptumRx say they have ironed out many of the problems with real-time benefit checks, which delivers out-of-pocket cost and prior approval information at the time a prescription is being written.
Gregory Warren Discusses Measuring Value and Scaling Up Value-Based Contracting
Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.
Digital Therapeutics: The Promise and Some Pitfalls |2022 PBMI Annual National Conference
Some of the evidence for digital therapeutic suffers from selection bias and relatively short studies, panelists at the Pharmacy Benefit Management Institute said today. They also discussed making the flood of data from the digital therapeutics accessible and useful to payers and clinicians.
Jeffrey Dunn on Prescription Digital Therapeutics | 2022 PBMI Annual National Conference
4 PBM Trends to Watch — And, Yes, Transparency is One of Them | Brandon Newman 2022 PBMI Annual National Conference
Brandon Newman, an industry veteran, also listed the specialty drug spend, collaboration and real-time optimization as the pharmacy benefit management trends to watch.
Extension Trial Shows Positive Results for Dupixent
Results reported at a meeting of the European Respiratory Society this week show a low rate of severe asthma attacks and sustained improvement in lung function among the children who participated in the yearlong add-on study.
What Does CVS Health’s Purchase of Signify Health Signify?
Jim Graham of Prime Therapeutics Discusses a Digital Transformation Management System in Healthcare
In this week's episode, MHE Editor Briana Contreras and Managing Editor Peter Wehrwein met with CIO of Prime Therapeutics, Jim Graham to discuss the process of an organization’s digital transformation from a traditional Pharmacy Benefit Manager to a complete data-driven drug management system. Graham addressed the risks an organization may come across to successfully transition to this system, but also mentioned the benefits to come.
Preschoolers Infected With SARS-CoV-2 Are More Likely To Be Asymptomatic Than Other Age Groups: Johns Hopkins Researchers
Findings reported in JAMA Network Open today show more than one-third of infected preschoolers are asymptomatic. The results call into question COVID-19 prevention strategies based on screening young children for symptoms.
Low-revenue MSSP ACOs Produced Better Results in 2021 Than High-revenue ACOs: CMS
The Centers for Medicare and Medicaid Services released results today showing that on a per capita basis, the net savings for low-revenue accountable care organizations (ACOs) was higher than the net savings for high-revenue ACOs.
Medicare Advantage Enrollment Trend: The “Up” Continues
Kaiser Family Foundation research shows that an 8% increase in enrollment from 2021 to 2022.
Biden Administration Increases Funding for ACA Navigators
The nearly $19 million boost comes after the Inflation Reduction Act extended enhanced premium tax credits for ACA marketplaces policies through 2025.
2022 Pharmacy Survey Results: PBMs | Part 6
Most of the respondents to the survey agreed that negotiations by pharmacy benefit managers (PBMs) lowers net drug prices. About half favored imposing transparency rules on PBMs.
2022 Pharmacy Survey Results: Aduhelm | Part 5
The respondents were almost evenly split on whether it was a mistake for the FDA to approve Aduhelm, but a large majority agreed that CMS made the right decision to restrict Medicare coverage to those enrolled in clinical trials.
2022 Pharmacy Survey Results: PrEP and Wegovy | Part 4
Opinion was split evenly on preexposure prophylaxis as a strategy for preventing HIV infections.
2022 Pharmacy Survey Results: Biosimilars | Part 3
Two-thirds of the respondents to our 2022 annual Pharmacy Survey believe that biosimilars will have a significant effect on drugs prices over the next several years.
2022 Pharmacy Survey Results: Drug Prices | Part 2
2022 Pharmacy Survey Results: COVID-19 | Part 1
Our survey shows some optimism about the course of the COVID-19 pandemic, but concern about Paxlovid rebound. Former President Donald Trump’s job performance on COVID-19 was rated low while the World Health Organization and Pfizer were rated high.
What Causes Long COVID?
Findings from a cros-sectional study reported by Yale and Mount Sinai researchers last week in a preprint last week linked long COVID to low levels of cortisol, the stress hormone, and possibly to reactivation of latent Epstein-Barr virus infections. Eric Topol called the study one of the best of long COVID so far.
Biomarkers for Graft-Versus-Host Disease | Part 4
In this concluding segment of a four-part series, Sophie Paczesny, M.D., Ph.D., of the Hollings Cancer Center of the Medical University of South Carolina and an expert on graft-versus-host disease biomarkers, discusses the future of biomarkers as companion diagnostics.
Biomarkers for Graft-Versus-Host Disease | Part 2
Biomarkers can be used for many purposes — diagnosis, prognosis, projections for success of a treatment. Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), reviews a typology of biomarkers that groups them into five subtypes and discusses their use in GVHD.
Biomarkers for Graft-Versus-Host Disease | Part 1
What is a biomarker? Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), explains.
The Healthcare Provisions in the Inflation Reduction Act
Pharma, health insurers square off about the healthcare provisions in the Inflation Reduction Act that passed the Senate yesterday. The PhRMA was sharply critical of the provisions that would empower CMS to negotiate the prices of a selected number of drugs. AHIP praised the extension of more generous ACA premium subsidies.
Zynteglo May Herald “New Dawn” of Many Seven-Figure Gene Therapies
An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.
It’s Time to Tame the “Diagnostic-Coding Arms Race”: NEJM Opinion Piece
The trend of primary care practices and businesses bearing risk has pitfalls.
A trio of experts have suggestions for how they can be avoided, including taking steps to de-emphasizing diagnostic coding in the calculations that determine payment.
Dialing Up Telehealth to Comprehensive Level Makes it More Effective: JAMA Internal Medicine Study
Results reported this week in JAMA Internal Medicine show a steeper decrease in HbA1C among people with poorly controlled type 2 diabetes who participated in a telehealth program that included telemonitoring, self-management support, medication management and services for depression. The comprehensive program cost about $1,500 more per year than the control program of standard telemonitoring and care coordination.
Medicare Drug Price Negotiation Included in Manchin, Schumer Deal
A joint statement from the two Democrats senators says prescription drug reform would save the federal government $288 billion over the next 10 years. Another provision extending enhanced ACA subsidies for three years has a $64 billion price tag.
2 Commerce Drive Cranbury, NJ 08512